OliX Pharmaceuticals Announces Results from Preclinical Study of NASH Therapeutic Candidate
August 04, 2021 09:00 ET
|
OliX Pharmaceuticals
- OLX702A reversed liver tissue damage in mouse model of NASH - Results and additional pipeline updates across hair loss, AMD and HBV programs presented at 48th KAST International Symposium -...
OliX Pharmaceuticals to Present at 2021 RNAi-Based Therapeutics Summit
June 14, 2021 10:00 ET
|
OliX Pharmaceuticals
SUWON, Republic of Korea, June 14, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that June Hyun Park, Ph.D.,...
OliX Pharmaceuticals to Conduct One-on-One Meetings with Potential Partners at BIO Digital 2021 Conference
June 10, 2021 15:00 ET
|
OliX Pharmaceuticals
SUWON, Republic of Korea, June 10, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will...
OliX Pharmaceuticals Signs Agreement with LGC Biosearch Technologies to Accelerate Production of Asymmetric siRNA for the Treatment of Androgenic Alopecia
June 09, 2021 10:00 ET
|
OliX Pharmaceuticals
SEOUL, Republic of Korea and LONDON, June 09, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, and LGC, a global leader in the life...
OliX Pharmaceuticals Subsidiary mCureX Announces Business Agreements to Advance Development of mRNA Vaccines and Therapeutics
June 07, 2021 08:00 ET
|
OliX Pharmaceuticals
SUWON, Republic of Korea, June 07, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced that the Company’s subsidiary mCureX has...
OliX Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for Improved Intracellular Delivery Platform Technology for RNAi Therapeutics
May 24, 2021 08:00 ET
|
OliX Pharmaceuticals
SUWON, Republic of Korea, May 24, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced that the Company has received a notice of...
OliX Pharmaceuticals Announces Results from Preclinical Study of Hair Loss Therapeutic Candidate
February 10, 2021 17:45 ET
|
OliX Pharmaceuticals
Company to discuss study results and present corporate overview at SMi’s 12th Annual RNA Therapeutics Virtual Conference on February 11 SUWON, Republic of Korea, Feb. 10, 2021 (GLOBE NEWSWIRE) --...
OliX Pharmaceuticals Launches New Subsidiary to Develop mRNA Vaccines and Therapeutics
February 08, 2021 07:00 ET
|
OliX Pharmaceuticals
SUWON, Republic of Korea, Feb. 08, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, has announced the establishment of mCureX...
OliX Pharmaceuticals to Present at 2021 ICR Conference
January 06, 2021 07:00 ET
|
OliX Pharmaceuticals
SUWON, Republic of Korea, Jan. 06, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will...
OliX Announces Completion of $37.2 Million Capital Raise to Support U.S. Expansion and Advance Pipeline Globally
December 01, 2020 07:00 ET
|
OliX Pharmaceuticals
Capital to fund construction of RNA synthesis GMP facility in San DiegoSupports company’s goal of having 10 programs entered into clinical trials by 2024 SUWON, Republic of Korea, Dec. 01, 2020 ...